Evidence map›Paper›PMID 27389009›Full record

ArticleACS synthetic biology2016

Full and Partial Agonism of a Designed Enzyme Switch.

S Jimmy Budiardjo, Timothy J Licknack, Michael B Cory, Dora Kapros, Anuradha Roy, Scott Lovell, Justin Douglas, John Karanicolas

Abstract read
In one paragraph

Article in ACS synthetic biology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Rescuing the Function of Missense-Mutated Tumor SuppressorbioRxiv : the preprint server for biology · 2026
    Article
  2. Article
  3. Allostery in Its Many Disguises: From Theory to Applications.Structure (London, England : 1993) · 2019
    Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

S Jimmy BudiardjoCenter for Computational Biology, ‡Department of Molecular Biosciences, §High Throughput Screening Laboratory, ∥Protein Structure Laboratory, ⊥Molecular Structures Group The University of Kansas , 2030 Becker Drive, Lawrence, Kansas 66045-7534, United States.
Timothy J LicknackCenter for Computational Biology, ‡Department of Molecular Biosciences, §High Throughput Screening Laboratory, ∥Protein Structure Laboratory, ⊥Molecular Structures Group The University of Kansas , 2030 Becker Drive, Lawrence, Kansas 66045-7534, United States.
Michael B CoryCenter for Computational Biology, ‡Department of Molecular Biosciences, §High Throughput Screening Laboratory, ∥Protein Structure Laboratory, ⊥Molecular Structures Group The University of Kansas , 2030 Becker Drive, Lawrence, Kansas 66045-7534, United States.
Dora KaprosCenter for Computational Biology, ‡Department of Molecular Biosciences, §High Throughput Screening Laboratory, ∥Protein Structure Laboratory, ⊥Molecular Structures Group The University of Kansas , 2030 Becker Drive, Lawrence, Kansas 66045-7534, United States.
Anuradha RoyCenter for Computational Biology, ‡Department of Molecular Biosciences, §High Throughput Screening Laboratory, ∥Protein Structure Laboratory, ⊥Molecular Structures Group The University of Kansas , 2030 Becker Drive, Lawrence, Kansas 66045-7534, United States.
Scott LovellCenter for Computational Biology, ‡Department of Molecular Biosciences, §High Throughput Screening Laboratory, ∥Protein Structure Laboratory, ⊥Molecular Structures Group The University of Kansas , 2030 Becker Drive, Lawrence, Kansas 66045-7534, United States.
Justin DouglasCenter for Computational Biology, ‡Department of Molecular Biosciences, §High Throughput Screening Laboratory, ∥Protein Structure Laboratory, ⊥Molecular Structures Group The University of Kansas , 2030 Becker Drive, Lawrence, Kansas 66045-7534, United States.
John KaranicolasCenter for Computational Biology, ‡Department of Molecular Biosciences, §High Throughput Screening Laboratory, ∥Protein Structure Laboratory, ⊥Molecular Structures Group The University of Kansas , 2030 Becker Drive, Lawrence, Kansas 66045-7534, United States.

Funding

WORD PROCESSING CENTER--COREP30CA006927 · NCI · RESEARCH INST OF FOX CHASE CAN CTR · PI Margaret von Mehren · 1985 to 2026
$138.8M
Mentoring CoreP20GM103418 · NIGMS · UNIVERSITY OF KANSAS MEDICAL CENTER · PI SUSAN J. BROWN · 2012 to 2026
$63.0M
Synthetic Chemical Biology CoreP20GM113117 · NIGMS · UNIVERSITY OF KANSAS LAWRENCE · PI ANTUNES, LUIS CAETANO MARTHA · 2016 to 2025
$23.9M
TRAFFICKING OF THE PLASMA MEMBRANE CA2+-ATPASE TO RAFTSP20RR017708 · NCRR · UNIVERSITY OF KANSAS LAWRENCE · PI FISCHER, CHRISTOPHER JAMES · 2002 to 2011
$20.1M
KU Post-Baccalaureate Research Education Program (PREP)R25GM078441 · NIGMS · UNIVERSITY OF KANSAS LAWRENCE · PI V GUSTAVO BLANCO, Paulyn Cartwright · 2006 to 2026
$6.6M
Protein Structure Laboratory P30GM110761 · NIGMS · UNIVERSITY OF KANSAS LAWRENCE · PI HANZLIK, ROBERT P · 2014 to 2018
$5.6M
PHARMACEUTICAL ASPECTS OF BIOTECHNOLOGY TRAININGT32GM008359 · NIGMS · UNIVERSITY OF KANSAS LAWRENCE · PI SIAHAAN, TERUNA J., VOLKIN, DAVID · 1989 to 2018
$5.0M
Protein Structure and FunctionP20GM103420 · NIGMS · UNIVERSITY OF KANSAS LAWRENCE · PI HANZLIK, ROBERT P · 2012 to 2012
$2.0M
NCI NIH HHS P30 CA006927NCRR NIH HHS P20 RR017708NIGMS NIH HHS P20 GM103418NIGMS NIH HHS P20 GM103420NIGMS NIH HHS P20 GM113117NIGMS NIH HHS P30 GM110761NIGMS NIH HHS R25 GM078441NIGMS NIH HHS T32 GM008359
6 · The paper itself

Abstract

Chemical biology has long sought to build protein switches for use in molecular diagnostics, imaging, and synthetic biology. The overarching challenge for any type of engineered protein switch is the ability to respond in a selective and predictable manner that caters to the specific environments and time scales needed for the application at hand. We previously described a general method to design switchable proteins, called "chemical rescue of structure", that builds de novo allosteric control sites directly into a protein's functional domain. This approach entails first carving out a buried cavity in a protein via mutation, such that the protein's structure is disrupted and activity is lost. An exogenous ligand is subsequently added to substitute for the atoms that were removed by mutation, restoring the protein's structure and thus its activity. Here, we begin to ask what principles dictate such switches' response to different activating ligands. Using a redesigned β-glycosidase enzyme as our model system, we find that the designed effector site is quite malleable and can accommodate both larger and smaller ligands, but that optimal rescue comes only from a ligand that perfectly replaces the deleted atoms. Guided by these principles, we then altered the shape of this cavity by using different cavity-forming mutations, and predicted different ligands that would better complement these new cavities. These findings demonstrate how the protein switch's response can be tuned via small changes to the ligand with respect to the binding cavity, and ultimately enabled us to design an improved switch. We anticipate that these insights will help enable the design of future systems that tune other aspects of protein activity, whereby, like evolved protein receptors, remolding the effector site can also adjust additional outputs such as substrate selectivity and activation of downstream signaling pathways.

Indexed as

Protein EngineeringAllosteric SiteBinding SitesGlucosidasesLigandsMagnetic Resonance SpectroscopyModels, MolecularMutationProtein BindingProtein ConformationProteinsStructure-Activity RelationshipGlucosidasesLigandsProteins

Identifiers

PMID27389009
PMCPMC5161622

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.